Procurement Summary
Country: USA
Summary: Analgesic Ketamine for Battlefield Use
Deadline: 12 Jan 2026
Other Information
Notice Type: Tender
TOT Ref.No.: 131947739
Document Ref. No.: HT9427-26-RFI-701
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_details
Login to see detailsTender Details
The purpose of this RFI is to address the OPMED WPAC PMO-s requirement for Tactical Combat Casualty Care (TCCC) solutions for acute severe pain from battlefield injuries. The OPMED WPAC PMO is conducting market research to determine the feasibility to collaborate with industry to develop, manufacturer, and receive U.S. Food and Drug Administration (FDA) approval of an analgesic ketamine product for procurement. All ketamine products for any route of administration will be considered, for example: autoinjectors, oral capsules, pumps, topical creams and patches, etc. OPMED WPAC PMO plans to release a request for proposals for the analgesic ketamine product in Fiscal Year 2026.
Please see list of attachments for other instructions.
Notice ID: ht9427-26-rfi-701
Department/Ind. Agency: dept of defense
Sub-tier: defense health agency (dha)
Office: defense health agency
Inactive Dates: jan 27, 2026
Inactive Policy: 15 days after response date
Documents
Tender Notice